Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100, 200/150, and 200/50 mg twice daily in HIV-negative volunteers
Main Authors: | Jackson, AGA, Hill, A, Else, LJ, Back, DJ, Morley, R, Puls, R, Amin, J, Lin, E, Boffito, M |
---|---|
Format: | Online |
Language: | English |
Published: |
The International AIDS Society
2010
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112961/ |
Similar Items
-
Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children
Published: (2015) -
Lopinavir/ritonavir monotherapy in clinical practice
by: Caso, A, et al.
Published: (2010) -
150 sukarelawan tanam 200 pokok berembang
by: Utusan Malaysia
Published: (2017) -
Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial
by: Cooper, David A., et al.
Published: (2016) -
Should the dose of tenofovir be reduced to 200–250 mg/day, when combined with protease inhibitors?
by: Hill, Andrew, et al.
Published: (2014)